Reproducibility of equivocal HER2 in situ hybridisation (ISH) results in invasive breast cancer, and correlation with HER2mRNA expression as determined by Mammatyper®

Riggi, Julia;Baez-Navarro, Ximena;Zylberberg, David;van der Made, Angelique;Van Bockstal, Mieke;et.al.
(2025) 19th St. Gallen International Breast Cancer Conference 2025 — Location: (Austria) Vienna (12.March.2025)

Files

2026_Riggi_StGallen_P052.pdf
  • Open Access
  • Adobe PDF
  • 77.53 KB
Download

Details

Authors
Show more
Abstract
(en) GOALS: Invasive breast cancers (IBC) with an equivocal HER2 immunohistochemical (IHC) score are subjected to in situ hybridization (ISH). Dual-probe ISH evaluates the mean HER2 and CEP17 copy numbers and the HER2/CEP17 ratio, to exclude or confirm HER2 amplification. IBCs are classified in five ISH groups, based on the 2018 ASCO/CAP guidelines, with ISH groups 2, 3 and 4 representing equivocal results. The goal of this study was to evaluate the reproducibility of HER2 ISH groups 3 and 4, and to correlate their HER2 mRNA expression level with the integrated IHC/ISH result. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Riggi, J., Baez-Navarro, X., Zylberberg, D., van der Made, A., Dubois, D., Vanderveken, J., Benhaddi, N., Duhoux, F., Vernaeve, H., Vassilieff, M., Berlière, M., Galant, C., van Deurzen, C., & Van Bockstal, M. (2025). Reproducibility of equivocal HER2 in situ hybridisation (ISH) results in invasive breast cancer, and correlation with HER2mRNA expression as determined by Mammatyper®. The Breast, 80(Suppl 1), 103935. https://doi.org/10.1016/j.breast.2025.103935 (Original work published 2025)